Model 1 | Model 2 | Model 3 | ||||
---|---|---|---|---|---|---|
β | P | β | P | β | P | |
Drug group (0 = glibenclamide; 1 = acarbose) | −0.113 | 0.410 | −0.192 | 0.127 | −0.183 | 0.126 |
Gender (0 = female; 1 = male) | 0.206 | 0.110 | - | - | - | - |
Age (years) | 0.134 | 0.307 | - | - | - | - |
Disease duration (years) | −0.132 | 0.313 | - | - | - | - |
BMI (kg/m2) | −0.217 | 0.179 | - | - | - | - |
HbA1c (%) | 0.730 | <0.001* | 0.718 | <0.001* | 0.698 | <0.001* |
MISI | −0.204 | 0.391 | −0.273 | 0.234 | - | - |
HOMA-IR | 0.384 | 0.080 | 0.265 | 0.148 | 0.308 | 0.085 |
HOMA-β (%) | 0.037 | 0.864 | −0.036 | 0.835 | - | - |
Insulinogenic index30 (pmol/mmol) | 0.091 | 0.734 | - | - | - | - |
AUCins120/AUCglu 120§(pmol/mmol) | −0.379 | 0.258 | −0.380 | 0.150 | −0.199 | 0.249 |
DI120 | 1.009 | 0.045* | 0.936 | 0.031* | 0.696 | 0.030* |
DI30 | −0.574 | 0.226 | −0.414 | 0.176 | −0.358 | 0.142 |